| This week's sponsor is Premier Research. | | | A Brand New Day for Rare Cancer Study
As cancer's molecular origins emerge and researchers join forces, it's a new day for study of rare oncology. Read our white paper for patient viewpoints and trends in trial design, regulation, and legislation. Premier Research. It's what we do. Best. |
| | | Flagship raises $285M special ops fund, changes name New drug approvals slump as early wins, CRLs hit rates CRUK research arm starts first-in-class Bicycle Therapeutics trial in cancer Amcure raises €6M in Series B, takes on Roche alumnus as new board member Novo boss sees stem cells as next big thing in diabetes: Bloomberg INC Research to add 550 jobs, move HQ, with potential funding from state FDA clears integration of J&J, Welldoc tech for real-time diabetes management New insight into cancer-associated liver enzymes could boost drug development Xtandi, cornerstone of Pfizer's $14B Medivation buy, falls short in closely watched study Genentech makes a quick CEO switcheroo, with Clark out, Anderson in | |
|
Top Stories Thursday, December 15, 2016 Record approvals of new drugs in 2014 and 2015 won't be repeated this year, but the number of filings is still at a very high level. So what is going on? Thursday, December 15, 2016 British research charity Cancer Research UK has teamed up with Bicycle Therapeutics, itself seeing the ink dry on a major deal with AstraZeneca this month, to trial BT1718 in advanced tumors. Thursday, December 15, 2016 German oncology biotech Amcure has secured a €6 million pot for its second formal round of funding as it looks to speed up the development of its leading candidate, AMC303. Thursday, December 15, 2016 It’s all very early stage, and a lot can happen from conception to first human trial (including many times not getting into human testing at all), but Novo Nordisk’s outgoing chief thinks his company is on to a potential cure for diabetes. Wednesday, December 14, 2016 INC Research, one of the largest CROs, is planning to move its headquarters to a nearby site in North Carolina, invest $38 million and add 550 new jobs over the next five years. Wednesday, December 14, 2016 In March, Johnson & Johnson tapped mobile health tech player Welldoc to incorporate its diabetes management platform into J&J’s latest blood glucose monitor. Now, the pair is announcing FDA clearance of the wireless integration between the two systems. Wednesday, December 14, 2016 Researchers at the University of California San Diego School of Medicine have found that the role of cancer-promoting and cancer-inhibiting enzymes is more complex than previously thought. The new findings improve understanding of how liver cancer develops and could lead to better therapies for the disease. Thursday, December 15, 2016 Pfizer rolled out the first round of new data since it closed on Xtandi-maker Medivation in September—and the results weren’t good. The blockbuster prostate cancer med fell short in a trial that might have supported longer-term treatment, a potentially lucrative prospect. Thursday, December 15, 2016 The CEO-replacement game continues in biopharma, and its latest round is playing out at Genentech. Roche’s U.S. unit has tapped Bill Anderson, a Roche executive, to replace 55-year-old Ian Clark, who’s retiring. | | | Roche has unexpectedly axed its diagnostics deal with Pacific Biosciences. Release Eye disease biotech Ocugen has closed a $6 million round of Series A funding as it looks to push on with testing for its lead med. Statement Immuno-oncology biotech Surface Oncology has taken on former Bluebird Bio exec Robert Ross as its new CMO. Release | |
|
Resources Presented By: Lenovo Get the stats you need to start down the path to a more secure infrastructure, today. Presented By: Lenovo What's the first step to a better patient experience? The patient experience starts well before the exam room or even reception - it begins as soon as your patients pull into the parking structure. Presented by: DocuSign DocuSign’s eSignature solutions modernize healthcare and life science organizations by eliminating paper and antiquated signature processes while meeting compliance requirements and reducing costs and errors. Presented by: DocuSign The patients who rely on your scientific leadership are expecting more. Presented by: DocuSign The U.S. Department of Justice has collected upwards of $17 billion in settlements from the healthcare industry since 2009, including more than $2 billion from a single life sciences company. Sponsored By: Salesforce Life sciences companies, like many industries today, face new challenges across the board. Read More. Presented By: ISR Reports Make essential outsourced bioprocessing decisions by staying informed of industry outsourcing practices and contract manufacturer usage patterns with ISR’s Bioprocessing Services and Technologies Market Trends and Outsourcing Dynamics report. Presented By: ISR Reports ISR’s Biosimilars in the US Oncology Market (2nd Edition) report provides data and insights from 101 US-based, board-certified oncologists/hematologist oncologists as to their expectations, fears, and aspirations for biosimilars in oncology. Presented By: ISR Reports Pinpoint the information oncologists find most valuable and the best sales channels for delivering specific types of data/information. Presented By: ISR Reports ISR’s Bioprocessing Market Trends and Outsourcing Dynamics: 2016-2021 report provides an overview of the current market dynamics for bioprocessing as well as an outlook on what the marketplace will look like in five years. Presented By: ISR Reports ISR’s CRO Quality Benchmarking – Phase II/III Service Providers (8th Edition) report provides a Consumer Reports-style analysis of Phase II/III CRO service quality from hundreds of users who rated 44 Phase II/III CROs across 26 critical dimensions of quality. Presented by: Patheon Can you avoid a risky trial-and-error approach to find the right path for your poorly soluble molecule by utilizing a CDMO? Download this complimentary Whitepaper to learn more! Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. FierceBiotech Executive Breakfast: Deciphering Immuno-Oncology, Trends in Deal-Making and R&D January 10, 2017 | San Francisco, CA Drug Development Boot CampTM 2017 November 15-16, 2017 | Boston, MA CBI’s IISR 2017 Summit February 14-15, 2017 | Philadelphia, PA Precision LBx Summit: Translating Next Generation Liquid Biopsies into Clinical Reality January 30-February 1, 2017 | San Diego, CA | 